ANALYST RECOMMENDATIONS : Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...

Every day, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information is used to shed light on the movements of certain stocks or the market sentiment on a company.

 

• Acushnet: Truist Securities adjusts price target to $48 from $56, maintains hold rating
• BAE Systems: DZ Bank downgrades to hold from buy. PT up 2.2% to 740 pence.
• Ball: BMO Capital Markets upgrades to outperform from market perform. PT up 19% to $105.
• Bristol-Myers Squibb: UBS adjusts price target to $70 from $61, maintains neutral rating
• Citigroup: Atlantic Equities downgrades to neutral from overweight. PT up 18% to $70.
• Foot Locker: UBS adjusts price target to $32 from $48, maintains neutral rating.
• Hikma: Morgan Stanley upgrades from Overweight to equal weight with a target of GBp 2300.
• Intel: Morgan Stanley downgrades to underweight from equal-weight. PT down 3.8% to $47.
• iQIYI: JPMorgan upgrades to overweight from neutral, raises price target to $8 from $5
• Neurocrine Bio: Piper Sandler downgrades to neutral from overweight. PT up 2.3% to $94.
• Polymetal: Berenberg remains Buy with a target reduced from GBp 1000 to GBp 500.
• Ross Stores: Morgan Stanley adjusts the price target to $137 from $140, maintains overweight rating
• Salesforce.com: Canaccord Genuity adjusts the price target to $260 from $315, maintains buy rating
• S&P Global: Morgan Stanley raises price target to $480 from $470, maintains overweight rating
• Target: Raymond James adjusts pt to $275 from $290, maintains strong buy rating
• Teradyne: Morgan Stanley downgrades to equal-weight from overweight. PT up 13% to $132.
• ZAI Lab Limited: SVB Leerink adjusts the price target to $102 from $194, maintains outperform rating